UK committee demands ‘much-needed clarity’ on UK-US pharma trade dealnews2025-12-19T00:01:46+00:00December 19th, 2025|Endpoints News|
Daiichi and Merck’s I-Dxd lung cancer study faces partial hold due to deathsnews2025-12-18T20:36:26+00:00December 18th, 2025|Endpoints News|
Endpoints biopharma sentiment survey for Q1 2026news2025-12-18T18:54:39+00:00December 18th, 2025|Endpoints News|
AI startup Edison raises $70M seed for research softwarenews2025-12-18T17:51:57+00:00December 18th, 2025|Endpoints News|
After year of triumph, Insmed stumbles with chronic rhinosinusitis fail, brings in new assetnews2025-12-18T16:35:36+00:00December 18th, 2025|Endpoints News|
Biopharma’s winners and losers of 2025news2025-12-18T16:20:28+00:00December 18th, 2025|Endpoints News|
Takeda’s $4B immunology drug achieves first Phase 3 successesnews2025-12-18T15:58:06+00:00December 18th, 2025|Endpoints News|
Subcutaneous Rybrevant; Kalaris shares nAMD data; Pyxis disappointsnews2025-12-18T15:47:22+00:00December 18th, 2025|Endpoints News|
Alnylam, INCOG and Novartis expand in US; Ember gets $16.5M Series Anews2025-12-18T14:57:00+00:00December 18th, 2025|Endpoints News|
Atavistik raises $120M for bleeding disorder, blood cancer drugsnews2025-12-18T13:59:04+00:00December 18th, 2025|Endpoints News|
